
    
      The study consisted of 2 parts, Part A and Part B. Part A was a double-blind,
      placebo-controlled assessment of safety and efficacy of VIVITROL versus placebo for 3 months.
      Part B was an open-label extension to assess longer-term safety, durability of effect, and
      health economics of VIVITROL when administered for up to 9 additional months.
    
  